Unique ID issued by UMIN | UMIN000010634 |
---|---|
Receipt number | R000012435 |
Scientific Title | Study for the efficacy and appropriate dosing of insulin degludec, an ultra long-acting insulin, in patients with type 1 diabetes |
Date of disclosure of the study information | 2013/05/01 |
Last modified on | 2015/03/31 13:21:29 |
Study for the efficacy and appropriate dosing of insulin degludec, an ultra long-acting insulin, in patients with type 1 diabetes
Study for the efficacy and appropriate dosing of insulin degludec, an ultra long-acting insulin, in patients with type 1 diabetes
Study for the efficacy and appropriate dosing of insulin degludec, an ultra long-acting insulin, in patients with type 1 diabetes
Study for the efficacy and appropriate dosing of insulin degludec, an ultra long-acting insulin, in patients with type 1 diabetes
Japan |
Type 1 diabetes mellitus
Endocrinology and Metabolism |
Others
NO
To evaluate the efficacy (changes in insulin dose and glycosylated hemoglobin) and safety (frequency of hypoglycemic events) of degludec by switching from other long-acting insulin (once daily or twice daily) in patients with type 1 diabetes.
Safety,Efficacy
Changes in HbA1c at 4, 12 and 24 weeks and insulin dose
Changes in mean blood glucose level, SD value, MAGE value, rate and duration of hyper/hypoglycemia, glycemic pattern and area under the carve after long-acting insulin injection, (evaluated by SMBG/CGM), body weight, and frequency of hypoglycemia
Interventional
Single arm
Non-randomized
Open -no one is blinded
Historical
1
Treatment
Medicine |
In patients those who are injecting long-acting insulin (1) once daily or (2) twice daily, long-acting insulin are switched to insulin degludec once daily injection. Initial degludec doses are transferred 1:1 from pretreated insulin (in group (2), the sum of two doses), or 80% for the cases with a risk of hypoglycemia. Insulin doses are then changed according to the protocol "KITANO Tresiba protocol".
20 | years-old | <= |
Not applicable |
Male and Female
1. Patients with type 1 diabetes who are on insulin basal-bolus therapy
2. Age: >20 years-old
1. The patients who did not agree with this study
2. The patients with serious complications
3. The patients who are at high risk for hypoglycemia
4. The patients who have the history of severe hypoglycemia (needed an emergency transport according to the hypoglycemia unawareness)
5. Those who are not approved to be eligible to this study by corresponding researcher or co-researchers
30
1st name | |
Middle name | |
Last name | Yoshiyuki Hamamoto |
Kitano Hospital, The Tazuke Kofukai Medical Research Institute
Center for Diabetes and Endocrinology
2-4-20 Ohgimachi, Kita-ku, Osaka, JAPAN
1st name | |
Middle name | |
Last name |
Kitano Hospital, The Tazuke Kofukai Medical Research Institute
Center for Diabetes and Endocrinology
2-4-20 Ohgimachi, Kita-ku, Osaka, JAPAN
06-6312-1221
Kitano Hospital, The Tazuke Kofukai Medical Research Institute
Center for Diabetes and Endocrinology, Kitano Hospital, The Tazuke Kofukai Medical Research Institute
Self funding
NO
2013 | Year | 05 | Month | 01 | Day |
Unpublished
Completed
2012 | Year | 11 | Month | 27 | Day |
2013 | Year | 03 | Month | 07 | Day |
2014 | Year | 10 | Month | 01 | Day |
2014 | Year | 10 | Month | 01 | Day |
2015 | Year | 03 | Month | 31 | Day |
2013 | Year | 05 | Month | 01 | Day |
2015 | Year | 03 | Month | 31 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000012435